in the article “Use of Next-Generation Sequencing in the regulated domain of drug development“, Pistoia Alliance’s Keith Nangle and Mike Furness discuss how Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making.


This article summarises some of the technical and regulatory challenges posed by these technologies and the efforts being made to address them.


Reproduced with kind permission from Drug Discovery World Winter 2017/18 Volume 19 Number 1.’


Download from the box below or click here.


Download the PDF file .